We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+6.68%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
+$596M
Cap. Flow
+$655M
Cap. Flow %
30.37%
Top 10 Hldgs %
48.34%
Holding
102
New
45
Increased
15
Reduced
8
Closed
34

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$93.9M
2
BIIB icon
Biogen
BIIB
+$87.9M
3
AKBA icon
Akebia Therapeutics
AKBA
+$64.3M
4
AVTR icon
Avantor
AVTR
+$61.3M
5
TMO icon
Thermo Fisher Scientific
TMO
+$48.9M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.4M
2
IMMU
Immunomedics Inc
IMMU
+$67.7M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$57M
4
HOLX
Hologic
HOLX
+$46.6M
5
EXEL icon
Exelixis
EXEL
+$44.9M

Sector Composition

Rank Sector Weight
1 Healthcare 80.12%
2 Technology 1.7%
3 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRNB
101
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
– –
-548,500
Closed -$32.8M
ZGNX
102
DELISTED
Zogenix, Inc.
ZGNX
– –
-97,870
Closed -$2.64M
1 2 3 4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM

Avidity Partners Management's Q3 2020 Portfolio in Review

As of Q3 2020, Avidity Partners Management held 102 positions worth $2.16B, up 38% from $1.56B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Avidity Partners Management deployed $655M of net new capital in Q3 2020, opening 45 new positions and adding to 15 existing holdings. Its largest new stake was Merck: 1,199,226 shares worth $94.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 92% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Exelixis, an estimated $44.9M trimmed.

  • Avidity Partners Management's largest Q3 2020 buy was Merck: 1,199,226 shares worth $94.9M.
  • Avidity Partners Management added most to Avantor in Q3 2020, an estimated $61.3M increase.
  • Avidity Partners Management's biggest Q3 2020 reduction was Exelixis, cutting an estimated $44.9M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q3 2020, selling an estimated $82.4M.
  • Avidity Partners Management's ten largest holdings make up 48% of its $2.16B portfolio in Q3 2020.
  • Avidity Partners Management opened 45 new positions and closed 34 in Q3 2020.
  • Avidity Partners Management's portfolio value rose 38% quarter-over-quarter to $2.16B.

Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.